Table 4. Treatment-emergent adverse events occurring in more than one patient.

	Phase I 20 mg/d (n = 3)		Phase I 30 mg/d (n = 3)		Phase II 3-h infusion (20 mg/d) (n = 7)		Phase II 24-h infusion (60 mg/d) (n = 5)		All (N = 18)
n	All grade	Grade ≥3	All grade	Grade ≥3	All grade	Grade ≥3	All grade	Grade ≥3	All grade	Grade ≥3
Euphoria	3	0	2	0	6	1	1	0	12	1
Somnolence	0	0	2	2	4	1	2	0	8	3
Ataxia	0	0	3	1	3	0	1	1	7	2
Dizziness	1	0	1	0	2	1	1	1	5	2
Confusion	0	0	2	1	1	0	2	0	5	1
Constipation	1		0		1		3		5
Fever	0	0	0	0	3	1	2	0	5	1
Diarrhea	1		1		1		1		4
Peripheral edema	0		0		2		2		4
Febrile neutropenia	0	0	1	1	2	2	1	1	4	4
Disorientation	2		0		1		0		3
Cough	0		1		2		0		3
Unsteady gait	0		1		2		0		3
Insomnia	1		0		2		0		3
Dyspnea	0		0		1		2		3
Hypoxia	0	0	0	0	3	1	0	0	3	1
Dysarthria	1		0		2		0		3
Fatigue	0	0	0	0	2	0	1	1	3	1
Headache	0		0		2		1		3
Ecchymosis	0		0		3		0		3
Hypotension	0		0		1		1		2
Tachycardia	0		0		2		0		2
Cardiac murmur	0		0		2		0		2
Atrial fibrillation	0	0	0	0	2	2	0	0	2	2
Pneumonia	1	1	0	0	1	1	0	0	2	2
Loose stool	1		0		1		0		2
Gingival pain	0		1		1		0		2
Cytokine release syndrome	1		0		1		0		2
Abnormal breath sounds	0		0		1		1		2
Acute MI	0	0	0	0	1	1	1	1	2	2
Dry mouth	0		0		1		1		2
Crackles (lung)	0		0		1		1		2
Thrush	0		0		2		0		2
Hypocalcemia	0		1		1		0		2
Hypokalemia	0		1		1		0		2
Slurred speech	0		0		2		0		2
Agitation	0	0	0	0	1	1	1	0	2	1
Muscular weakness	0		0		1		1		2
Anxiety	0		1		1		0		2